TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32480417

Group type: EXPERIMENTAL
Intervention: VWF:Ag and VWF:GPIbM levels postoperatively
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Blood type non-O or medium risk surgery
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: VWFpp/VWF:Ag ratio immediately after surgery
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Lowest VWF:Ag quartile (0.43-0.92 IU/mL)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: VWF levels
Number of subjects: 59
Study: 35078765

Group type: EXPERIMENTAL
Intervention: SOC-F (fosfomycin at 100 mg/kg two times per day for up to 7 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: SOC (standard-of-care antibiotics)
Number of subjects: 120
Study: 33482769

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously once every 4 weeks, with loading doses on study days 8 and 15
Number of subjects: 526
Study: 34148781

Group type: EXPERIMENTAL
Intervention: Cannabis preparations (most commonly cannabidiol)
Number of subjects: 312

Group type: COMPARATOR
Intervention: No cannabis use (control group)
Number of subjects: 312
Study: 32243402

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine combined with western medicine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional Western medicine treatment
Number of subjects: 60
Study: 35622826

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Standard perioperative management
Number of subjects: 2400
Study: 34046496

Group type: EXPERIMENTAL
Intervention: TheraCal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 30

Group type: COMPARATOR
Intervention: MTA
Number of subjects: 30
Study: 32323046

Group type: EXPERIMENTAL
Intervention: SOLACE (8-week psychosocial stigma protection intervention)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 17
Study: 35435321

Group type: EXPERIMENTAL
Intervention: Immediate moisturizing after washing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Delayed moisturizing at 30 minutes after washing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non‐moisturized skin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Immediate moisturizing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Delayed moisturizing
Number of subjects: 60
Study: 32074247

Group type: EXPERIMENTAL
Intervention: COAPT study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MITRA-FR study
Number of subjects: 0
Study: 33929598

Group type: EXPERIMENTAL
Intervention: Non-White patients
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: Patients aged > 65
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 5380
Study: 34838412

Group type: EXPERIMENTAL
Intervention: DiaLife education program for relatives of adults with diabetes
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (waiting list condition)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: DiaLife education program for relatives of people with type 2 diabetes
Number of subjects: 179
Study: 33010470

Group type: EXPERIMENTAL
Intervention: Self‐paced, interactive, multimedia module (SPM)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Traditional didactic session (TDS)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Both groups (SPM and TDS)
Number of subjects: 127
Study: 32441241

Group type: EXPERIMENTAL
Intervention: Methionine plus cystine (Met+Cys) intake at 313 mg/day for P1 (2 to 6 weeks)
Number of subjects: 1448

Group type: EXPERIMENTAL
Intervention: Methionine plus cystine (Met+Cys) intake at 381 mg/day for P2 (8 to 12 weeks)
Number of subjects: 1448

Group type: EXPERIMENTAL
Intervention: Methionine plus cystine (Met+Cys) intake at 318 mg/day for P3 (14 to 18 weeks)
Number of subjects: 1448

Group type: EXPERIMENTAL
Intervention: Methionine plus cystine (Met+Cys) requirements for WG: 20 mg/g for P1, 22 mg/g for P2, 27 mg/g for P3
Number of subjects: 1448

Group type: EXPERIMENTAL
Intervention: Methionine plus cystine (Met+Cys) requirements for maintenance: 214 mg/kgBW0.75 for P1, 53 mg/kgBW0.75 for P2, 30 mg/kgBW0.75 for P3
Number of subjects: 1448
Study: 35866585

Group type: EXPERIMENTAL
Intervention: Exercise training (three to four times per week for 25-40 minutes at 50%-70% of heart rate reserve)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34803547

Group type: EXPERIMENTAL
Intervention: Situated simulation-based (SSB) program with standardized child patients
Number of subjects: 62

Group type: COMPARATOR
Intervention: Video training (control group)
Number of subjects: 62
Study: 32867994

Group type: EXPERIMENTAL
Intervention: Dietary lead nitrate at 3.20 mg/kg
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Dietary lead nitrate at 33.20 mg/kg
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Dietary lead nitrate at 63.20 mg/kg
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Dietary lead nitrate at 93.20 mg/kg
Number of subjects: 512
Study: 36008074

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) device, 8-week home-based intervention, footplate stimulation for 30 minutes daily and quadriceps stimulation for 20 minutes, five times a week.
Number of subjects: 193

Group type: COMPARATOR
Intervention: Sham device, 8-week home-based intervention.
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: NMES device
Number of subjects: 193

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 193
Study: 34524395

Group type: EXPERIMENTAL
Intervention: Heavy-weight polypropylene mesh
Number of subjects: 350

Group type: COMPARATOR
Intervention: Medium-weight polypropylene mesh
Number of subjects: 350
Study: 33728637

Group type: EXPERIMENTAL
Intervention: New approach to reducing substance use (details not specified)
Number of subjects: 0
Study: 36255569

Group type: EXPERIMENTAL
Intervention: Baricitinib (2 mg and 4 mg extended)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: All baricitinib doses
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study: 36141644

Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 53

Group type: COMPARATOR
Intervention: Meat-rich diet
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 53
Study: 33243667

Group type: EXPERIMENTAL
Intervention: Scandinavian Obesity Surgery Registry (SOReg) data collection
Number of subjects: 34628

Group type: EXPERIMENTAL
Intervention: Reabstracted data from SOReg
Number of subjects: 34628

Group type: EXPERIMENTAL
Intervention: Variables studied in SOReg
Number of subjects: 34628

Group type: EXPERIMENTAL
Intervention: Mandatory variables in SOReg
Number of subjects: 34628
Study: 35708631

Group type: EXPERIMENTAL
Intervention: KGR-BG1 (1500 mg oral dose containing 1000 mg active component, twice daily for 6 weeks)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Korean Red Ginseng Extract (1500 mg oral dose containing 1000 mg active component, twice daily for 6 weeks)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (1500 mg oral dose, twice daily for 6 weeks)
Number of subjects: 180
Study: 32051147

Group type: EXPERIMENTAL
Intervention: Low-dose Sinemet (levodopa plus carbidopa) for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose Sinemet (levodopa plus carbidopa) for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects (no diabetes)
Number of subjects: 0
Study: 32564076

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 10 mg/kg daily for 12 months
Number of subjects: 300

Group type: COMPARATOR
Intervention: No Isoniazid (no INH)
Number of subjects: 300
Study: 32295423

Group type: EXPERIMENTAL
Intervention: Arterial events (critical limb ischemia or stroke)
Number of subjects: 1082

Group type: COMPARATOR
Intervention: Age- and sex-matched controls
Number of subjects: 1082
Study: 35176678

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) twice weekly
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT) once weekly
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT) twice weekly
Number of subjects: 200

Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT) once weekly
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: IPT skills
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Change in depression
Number of subjects: 200
Study: 36448389

Group type: EXPERIMENTAL
Intervention: PVRU of 200 ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: PVRU of 300 ml
Number of subjects: 0
Study: 33725616

Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HT)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 152
Study: 33377369

Group type: EXPERIMENTAL
Intervention: Camellia seed oil (CSO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soybean oil
Number of subjects: 0
Study: 35445883

Group type: EXPERIMENTAL
Intervention: Intervention group (tailored clinic staff training on postpartum depression, awareness raising, and social support)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Intervention group (high PPD awareness)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Both groups (high social support)
Number of subjects: 332
Study: 33727268

Group type: EXPERIMENTAL
Intervention: Local consolidation radiation therapy (RT) and standard maintenance therapy
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard maintenance therapy
Number of subjects: 190
Study: 32715427

Group type: EXPERIMENTAL
Intervention: Artificial intelligence and precision mental health approaches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 34134684

Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg twice daily (BID)
Number of subjects: 1686

Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily (QD)
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1686
Study: 32761610

Group type: EXPERIMENTAL
Intervention: Genetically predicted magnesium concentration (1 SD higher, SD: 0.08 mmol/L)
Number of subjects: 228951

Group type: EXPERIMENTAL
Intervention: Genetically predicted phosphorus concentration (1 SD higher, SD: 0.5 mg/dL)
Number of subjects: 228951
Study: 34501569

Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 233

Group type: COMPARATOR
Intervention: Gain-framed message
Number of subjects: 233
Study: 32422113

Group type: EXPERIMENTAL
Intervention: Subthreshold 532 nm Diode Micropulse Laser (SML)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional Laser Photocoagulation (CLP)
Number of subjects: 60
Study: 36228641

Group type: EXPERIMENTAL
Intervention: Colchicine 1·2 mg followed by 0·6 mg 2 h later and then 0·6 mg twice daily for 28 days
Number of subjects: 2749

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2·5 mg twice daily plus aspirin 100 mg once daily for 28 days
Number of subjects: 2749

Group type: COMPARATOR
Intervention: Control (usual care) for colchicine
Number of subjects: 2749

Group type: COMPARATOR
Intervention: Control (usual care) for rivaroxaban and aspirin
Number of subjects: 2749

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 2749

Group type: EXPERIMENTAL
Intervention: Rivaroxaban and aspirin
Number of subjects: 2749
Study: 33245168

Group type: EXPERIMENTAL
Intervention: Sarcosine (2 g daily)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 35091440

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 4047
Study: 34118178

Group type: EXPERIMENTAL
Intervention: Mobocertinib (TAK-788) 20-160 mg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Mobocertinib (120/160 mg) under fasted or low-fat meal conditions
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Mobocertinib 160 mg in 1 of 2 capsule products
Number of subjects: 69
Study: 32151367

Group type: EXPERIMENTAL
Intervention: Naldemedine 0.2 mg once daily for 2 weeks (COMPOSE-4)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Naldemedine 0.2 mg once daily for 12 weeks (COMPOSE-5)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Naldemedine 0.2 mg
Number of subjects: 324
Study: 34363708

Group type: COMPARATOR
Intervention: Erenumab 140 mg
Number of subjects: 375

Group type: COMPARATOR
Intervention: Erenumab 70 mg
Number of subjects: 375
Study: 33706345

Group type: EXPERIMENTAL
Intervention: Any breastfeeding
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Each additional month of breastfeeding
Number of subjects: 772

Group type: COMPARATOR
Intervention: No breastfeeding
Number of subjects: 772
Study: 34508607

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (300,000 IU cholecalciferol followed by 1400 IU cholecalciferol + 500 mg of calcium daily for 150 days)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo (n=156)
Number of subjects: 307
Study: 32428912

Group type: EXPERIMENTAL
Intervention: 0.3% Retinol Serum
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 0.5% Retinol Serum
Number of subjects: 37

Group type: COMPARATOR
Intervention: Study Vehicle (Control)
Number of subjects: 37
Study: 35421407

Group type: EXPERIMENTAL
Intervention: Dentapen (1.8 mL/162 sec, ramp-up setting)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Traditional syringe (1.8 mL/60 sec)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Dentapen
Number of subjects: 130
Study: 33547257

Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study: 32847902

Group type: EXPERIMENTAL
Intervention: TAU plus access to My Journey 3 on their own Smartphone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual from EIP services (TAU)
Number of subjects: 40
Study: 35621117

Group type: EXPERIMENTAL
Intervention: Existing blood donor eligibility questionnaire
Number of subjects: 903

Group type: COMPARATOR
Intervention: Modified donor questionnaire that repositioned the MSM question among neutral questions
Number of subjects: 903
Study: 33247448

Group type: EXPERIMENTAL
Intervention: 50 nM EBR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 nM EBR
Number of subjects: 0
Study: 32002769

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 736

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Rivaroxaban and Warfarin
Number of subjects: 736
Study: 36413125

Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray after an overnight fast
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diazepam nasal spray after a standardized high-fat, high-calorie breakfast
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fasted conditions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fed conditions
Number of subjects: 20
Study: 33592892

Group type: EXPERIMENTAL
Intervention: Modified seton cutting technique
Number of subjects: 204

Group type: COMPARATOR
Intervention: Cutting seton technique
Number of subjects: 204
Study: 34125734

Group type: EXPERIMENTAL
Intervention: Intention-to-treat (ITT) analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average treatment effect (ATE) with no assumptions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average treatment effect (ATE) with minimum assumptions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complier average treatment effect (complier ATE)
Number of subjects: 0
Study: 33387498

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) with prescribed doses ranging from 24–60 Gy administered in three to eight fractions.
Number of subjects: 1422

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR)
Number of subjects: 1422
Study: 34197323

Group type: EXPERIMENTAL
Intervention: Image reconstruction network with residual block structure and perceptual loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Image reconstruction network with randomization layers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Image reconstruction network
Number of subjects: 0
Study: 32134984

Group type: EXPERIMENTAL
Intervention: Medical crowdfunding campaigns organized by individuals
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Campaign characteristics under users' control (photos, videos, updates)
Number of subjects: 637
Study: 35428627

Group type: EXPERIMENTAL
Intervention: IPRP + eVIS
Number of subjects: 400

Group type: COMPARATOR
Intervention: IPRP only
Number of subjects: 400
Study: 33539760

Group type: EXPERIMENTAL
Intervention: HIV clinic-based buprenorphine plus naloxone treatment
Number of subjects: 281

Group type: COMPARATOR
Intervention: Referral for methadone maintenance therapy
Number of subjects: 281
Study: 35879007

Group type: EXPERIMENTAL
Intervention: Improved maternity waiting homes (MWH) model
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (no improved MWH model)
Number of subjects: 158
Study: 33791930

Group type: EXPERIMENTAL
Intervention: Tailored gain-framed message
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Tailored gain-framed communication
Number of subjects: 808

Group type: COMPARATOR
Intervention: Non-tailored message
Number of subjects: 808
Study: 32434934

Group type: EXPERIMENTAL
Intervention: Informed consent documents from hospitals
Number of subjects: 2480
Study: 35050355

Group type: EXPERIMENTAL
Intervention: Urolithin A (1000 mg daily for 4 months)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 32928313

Group type: EXPERIMENTAL
Intervention: 0.2% Povidone-Iodine gargle and nasal lavage, 10 ml, for 20-30 seconds, thrice daily for 6 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1% Hydrogen peroxide gargle and nasal lavage, 10 ml, for 20-30 seconds, thrice daily for 6 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Neem extract (Azardirachta indica) gargle and nasal lavage, 10 ml, for 20-30 seconds, thrice daily for 6 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2% hypertonic saline gargle and nasal lavage, 10 ml, for 20-30 seconds, thrice daily for 6 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Distilled water gargle and nasal lavage, 10 ml, for 20-30 seconds, thrice daily for 6 days
Number of subjects: 50
Study: 36167636

Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg twice daily) plus sertraline (100 mg daily initially followed by 200 mg daily after week 4)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo plus sertraline (100 mg daily initially followed by 200 mg daily after week 4)
Number of subjects: 58
Study: 33315105

Group type: EXPERIMENTAL
Intervention: 150 mg nilotinib
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 300 mg nilotinib
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 35072420

Group type: EXPERIMENTAL
Intervention: Coverage of all buccal cusps (T2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Coverage of all cusps (T6)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Other types of cuspal coverage (T1, T3, T4, T5)
Number of subjects: 60
Study: 33085056

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33892089

Group type: EXPERIMENTAL
Intervention: Intervention implemented in stepped wedge trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control clusters
Number of subjects: 0
Study: 32886012

Group type: EXPERIMENTAL
Intervention: First-episode psychosis patients (FEPP)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients (SPP)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Healthy volunteers (Control)
Number of subjects: 119
Study: 35685610

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 34102649

Group type: EXPERIMENTAL
Intervention: Survived mass shooters with psychiatric diagnosis
Number of subjects: 35

Group type: COMPARATOR
Intervention: Mass shooters who died
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mass shooters with psychiatric illnesses
Number of subjects: 35
Study: 33009147

Group type: EXPERIMENTAL
Intervention: Hybrid LD flap
Number of subjects: 89

Group type: COMPARATOR
Intervention: Abdominal-based free flap
Number of subjects: 89
Study: 33176756

Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Hall Technique (HT)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Both ART and HT
Number of subjects: 131
Study: 32156175

Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 66

Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 66
Study: 32410687

Group type: EXPERIMENTAL
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Typical angina
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Atypical angina
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Non-anginal chest discomfort
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1263

Group type: COMPARATOR
Intervention: Obstructive CAD
Number of subjects: 1263
Study: 616264954

Group type: EXPERIMENTAL
Intervention: Bone tunnel impaction technique using dilators
Number of subjects: 31

Group type: COMPARATOR
Intervention: Regular extraction bone tunnel drilling
Number of subjects: 31
Study: 35655314

Group type: EXPERIMENTAL
Intervention: BIDI® Stick ENDS
Number of subjects: 18

Group type: COMPARATOR
Intervention: JUUL ENDS
Number of subjects: 18
Study: 33291142

Group type: EXPERIMENTAL
Intervention: Self-measurement of urinary chloride
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 138
Study: 35361700

Group type: EXPERIMENTAL
Intervention: cTBS
Number of subjects: 120

Group type: COMPARATOR
Intervention: 1 Hz rTMS
Number of subjects: 120

Group type: COMPARATOR
Intervention: sham cTBS
Number of subjects: 120
Study: 33399416

Group type: EXPERIMENTAL
Intervention: Baseline GCIPL thickness in RRMS
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Baseline GCIPL tertiles in RRMS
Number of subjects: 180

Group type: COMPARATOR
Intervention: Baseline pRNFL and GCIPL thickness
Number of subjects: 180
Study: 32071190

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Sham transcutaneous tibial nerve stimulation (sham TTNS)
Number of subjects: 208